Department of Obstetrics and Gynaecology, Mianzhu People's Hospital, Mianzhu, China.
Department of Obstetrics and Gynaecology, Southwest Medical University, Luzhou, Sichuan, China.
BMJ Open. 2021 Jan 17;11(1):e043141. doi: 10.1136/bmjopen-2020-043141.
Uterine serous carcinoma accounts for only about 10% of all endometrial cancers but this subtype is the most common amongst non-endometrioid endometrium cancers and contributes to more than half of recurrence and deaths attributed to endometrial cancers. A more extensive surgical staging and adjuvant therapies for uterine serous carcinoma are recommended by many guidelines. However, guidelines vary on recommendations for the methods that should be used for omentum assessment in uterine serous carcinoma and the previously reported incidence of omental metastasis in uterine serous carcinoma had a wide range because of the heterogeneity among these studies. As far as we know, there are no systematic review and meta-analysis available on this topic. The aim of our proposed study is to statistically synthesise the data examining the incidence of omental metastasis in uterine serous carcinoma.
Systematic searches of three databases (PubMed, Embase and Web of Science) will be performed using prespecified search strategies. We will include original studies that reported incidence of omental metastasis in uterine serous carcinoma and are published before 30 August 2020. Our different investigators will independently conduct the eligible study selection, assess the quality of included studies and extract the needed data. If appropriate, the relevant data will be pooled through a random-effect or fixed-effect meta-analysis based on the heterogeneity among included studies. We will evaluate the overall quality of evidence using appropriate methods.
This proposed study will be based on published data, and thus, there is no requirement for ethics approval. We aim to publish the results of this study in a peer-reviewed journal with good visibility for the fields of gynaecology and gynecologic oncology.
CRD42020200891.
子宫浆液性癌仅占所有子宫内膜癌的 10%左右，但在非子宫内膜样子宫内膜癌中最为常见，占子宫内膜癌复发和死亡的一半以上。许多指南建议对子宫浆液性癌进行更广泛的手术分期和辅助治疗。然而，指南对子宫浆液性癌中网膜评估应采用的方法的建议存在差异，由于这些研究之间存在异质性，以前报道的子宫浆液性癌中网膜转移的发生率范围很广。据我们所知，目前尚无关于这一主题的系统评价和荟萃分析。我们拟议研究的目的是统计综合分析检查子宫浆液性癌中网膜转移发生率的数据。
将使用预设的搜索策略对三个数据库（PubMed、Embase 和 Web of Science）进行系统搜索。我们将纳入报告子宫浆液性癌中网膜转移发生率的原始研究，并于 2020 年 8 月 30 日前发表。我们的不同调查人员将独立进行合格的研究选择、评估纳入研究的质量并提取所需的数据。如果合适，将根据纳入研究之间的异质性，通过随机效应或固定效应荟萃分析对相关数据进行汇总。我们将使用适当的方法评估证据的总体质量。
本研究基于已发表的数据，因此不需要伦理批准。我们旨在将研究结果发表在一个同行评议的期刊上，该期刊在妇科和妇科肿瘤学领域具有良好的可见度。
PROSPERO 注册号：CRD42020200891。
